The MEDDIC Sales Process, and Why the Letters Are the Easy Part

A good doctor does not diagnose from across the waiting room. She could, often, and be right more than chance would allow, the gray pallor, the careful way a man holds one side as he sits. But she does not stake your life on the look of you. She takes the vitals first: the pressure, the pulse, the blood drawn and sent down the hall. The numbers are not the diagnosis. They are the thing that keeps the diagnosis honest, the cold facts that do not care how hopeful anyone felt that morning.

A sales forecast is a diagnosis, and most are made from across the waiting room. A rep looks at a deal, likes the champion, remembers a good call, and writes “commit” next to a number. It feels like judgment. It is mostly the gray pallor and a hopeful morning. MEDDIC is the set of vitals for a deal, the readings you take so the call you make next quarter is grounded in something colder than how the last conversation felt.

What is the MEDDIC sales process?

The MEDDIC sales process is a qualification framework that forces a rep to replace their optimism about a deal with six facts they can prove. It was built at Parametric Technology Corporation in the 1990s, during the years the company grew from around 300 million dollars to more than a billion, and the people who ran that sales floor, Dick Dunkel and Jack Napoli chief among them, left with a discipline that has outlived the company and spread through enterprise software ever since.

Strip away the acronym and MEDDIC is one idea, repeated six times: stop telling yourself a story about the deal, and go find out what is true. A rep who “feels good” about a deal has a story. A rep who can name the number the buyer will move, the person who controls the budget, and the insider who will argue the case when the room is closed, has evidence. The gap between those two reps is the gap between a forecast you can bank and one you cross your fingers over.

What does MEDDIC stand for?

Six letters, each a fact about the buyer, not a thing you did. Take them one at a time, because the difference between knowing the word and knowing the deal lives in the detail.

• Metrics. The economic result the buyer is trying to move, stated as a number they own. Not “improve efficiency,” but “cut ramp time from nine months to five.” If you cannot put a figure on the prize, the buyer has not decided it is worth chasing, and neither have you.
• Economic buyer. The one person who can free the money when everyone else can only ask for it. Champions are common; economic buyers are scarce, and a deal that has never met one is a deal sold to people who can say no but never yes.
• Decision criteria. The standard the buyer will judge you against, technical, commercial, and political. Win the criteria early and you have shaped the race. Learn them at the proposal stage and you are running someone else’s.
• Decision process. The literal sequence of who signs what, in what order, and by when. This is the map of the buyer’s machine, and a deal with no decision process named is a deal whose close date you invented.
• Identify pain. The specific cost the buyer feels now, sharp enough to act on this year. Mild pain produces pleasant conversations and no purchase orders. Qualified pain has a price tag and a deadline the buyer, not you, supplied.
• Champion. The insider with power and a personal stake in your win, who will sell for you when you are not in the room. The test is simple and most “champions” fail it: will this person spend their own credibility to push your deal forward, or do they only enjoy the meetings?

That last distinction is the one teams get wrong most, so it earns a picture. A coach likes you. A champion fights for you. A coach takes your calls, shares the gossip, tells you that you are doing great. A champion stands up in the budget meeting you were never invited to and spends real capital arguing that the company should buy. You can have a dozen coaches and zero champions, and the deal will feel warm right up to the day it dies.

Is MEDDIC a sales process or a qualification methodology?

It is a methodology, and the confusion is not pedantic, it is the reason most rollouts fail. A sales process is where a deal sits on its path, the stages from prospect to close. A methodology is how you work inside those stages. The stages tell you where you are; MEDDIC tells you whether the ground under you is solid. You want both, and they answer different questions, which is the same point we draw out in the seven sales process steps and in what a sales process is.

Here is why the difference bites. A team that treats MEDDIC as a process bolts six new fields onto the CRM, declares the rollout done, and waits for better forecasts that never come. The fields fill up with the same optimism they were meant to replace, because nobody checks whether “Economic buyer: confirmed” means the rep met them or merely hopes they exist. MEDDIC was never a place to store answers. It is a standard for whether the answers are true.

What about MEDDICC and MEDDPICC?

Same spine, more vertebrae for deals that need them. MEDDICC adds a second C for Competition, because a deal you are winning on the merits can still be lost to a rival you never asked about. MEDDPICC adds a P for Paper process, the procurement, legal, and security review that ambushes late-stage deals nobody qualified for. The bigger and more regulated the purchase, the more those two letters earn their place, because the rival and the redline are precisely where a confident pipeline tends to come apart. If your deals routinely stall in legal, you do not have a closing problem. You have a P you never qualified.

Why do most MEDDIC rollouts fail?

Because teams install the acronym and skip the behavior, and the acronym was always the easy part. Any rep can recite six letters by Friday. A chatbot can define them in a sentence. What is hard, what was always hard, is getting a busy rep to do the cold, slightly deflating work of MEDDIC on a real deal on a Tuesday: to call the friendly contact and discover they cannot sign, to ask the question whose honest answer demotes a “commit” to a “best case.”

That work is unpleasant, which is why it gets skipped, and the cost of skipping it is enormous. In The Jolt Effect, Matt Dixon and Ted McKenna studied more than two and a half million sales conversations and found that between 40 and 60 percent of qualified, interested buyers end in no decision, not lost to a competitor but lost to their own inability to move (Matt Dixon and Ted McKenna, The Jolt Effect, 2022). Read that against MEDDIC and the framework reveals what it is for: most of those dead deals had pain that was real but not sharp, a champion who was only ever a coach, a decision process nobody mapped. MEDDIC is a machine for catching exactly that, but only if a rep runs it, and only if someone can see whether they did.

That visibility is the part no acronym supplies. We asked 198 sales leaders about it, and the answer was stark: 89 percent had a defined sales process and only 36 percent saw their reps follow it (The State of Sales Enablement). A methodology adopted on paper and ignored in the field is not a methodology. It is a poster.

And the modern buyer makes the discipline more valuable, not less. Gartner finds B2B buyers spend only about 17 percent of the buying journey in contact with all the suppliers they are weighing, combined, and that the deciding group now runs from six to ten people who often fall into open disagreement before they choose (Gartner). When you can watch only a sixth of the real decision, you cannot afford to forecast on vibes. The MEDDIC facts, who controls the money, how the choice gets made, who will fight for you, are the few honest readings you get from a machine running mostly out of view.

What do the people who own MEDDIC say is the hard part?

It is worth pausing here, because we are not the first to notice that the letters are easy and the doing is hard. The two groups who teach MEDDIC to most of the sales world say the same thing, in their own words, and they are worth hearing in full before we add ours.

John Kaplan ran on that PTC sales floor in the 1990s and built Force Management on what he learned there. His picture for MEDDIC is a good one, close to our own. He calls it an X-ray. “You can’t fix your deals or solve your forecasting issues,” Kaplan says, “without having both the x-ray to identify gaps and the treatment so you can fix them.” Force Management is blunt about the failure mode too: “Many sales teams using MEDDIC today treat it as a simple checklist,” they write, and the revenue shows up only when a team runs it as a repeatable process instead. Grant all of it. The x-ray is real, the rigor wins, and a team that qualifies hard beats a team that hopes.

Andy Whyte, whose 2020 book MEDDICC sold past a hundred thousand copies and put the framework in front of a generation of reps, lands on the same nerve from the Champion. He keeps alive the maxim Jack Napoli and Steve Amman coined at the Sales MEDDIC Group: “No Champion, no deal. Big Champion, Big deal!” That line draws the same hard edge: a friendly contact is not the thing. The thing is a person with real power who will spend their own credibility for you, and finding out which one you have is work a rep has to do, on a real deal, this week.

So the field already agrees on the diagnosis. The acronym is the easy part. The honest qualifying is the hard part. Here is where we go one step further, and it is a step Kaplan’s own picture invites.

An X-ray finds the fracture. It never sets the bone. The reading is taken in a moment, and the healing happens, or does not, in the days that follow, when someone acts on what the film showed. MEDDIC has the same two halves. The film is the six facts. The treatment is a rep, on a Tuesday, calling the friendly contact to find out they cannot sign, asking the question whose honest answer demotes a “commit” to a “best case.” And the treatment only works if it happens while the deal is still alive, in the moment the rep is working it, not weeks later when the film is read aloud at a pipeline review and the break has already set wrong.

This is where MEDDIC stops being a noun and becomes a verb, and it is the part a CRM field cannot hold. Storing “Economic buyer: confirmed” is the film. It is not the treatment. The treatment is qualification as a behavior: the cold, slightly deflating act performed in the flow of the deal, then inspected so a manager can tell the difference between a rep who met the economic buyer and one who hopes one exists. Storage is the solved problem in 2026. Any tool can hold the answer; any rep or chatbot can recite the six letters. What is unsolved is making the qualifying happen in the moment and seeing whether it did. Tellingly, both camps now agree: Force Management built Xcelerator for AI-guided execution, and MEDDICC built Winni AI and a deal scorer to push the test into the rep’s day. The field is converging on the same conclusion. The film was never enough; the work has to reach the rep while the deal is open.

How do you make MEDDIC stick?

So here is the way forward, and it is shorter than the problem makes it sound.

• Score the deal, do not store the deal. MEDDIC is a test, not a tab. Each letter gets a real, defensible answer or it gets marked unknown. “Unknown” is the most valuable word in the framework, because it tells the rep exactly where the deal is blind.
• Reach the rep in the moment, not in a quarterly review. The qualification question has to arrive when the rep is working the deal, not weeks later in a pipeline meeting where the honest answer is too late to change anything. This is the deeper subject of sales process adoption and of the sales execution gap.
• Measure the answers, not the activity. A logged call records how hard a rep worked. A confirmed economic buyer records that the deal moved. Track both, advance on the second, and your forecast stops flattering you. This is also why thin qualification wrecks the sales forecast long before quarter close.

MEDDIC pairs naturally with the other sales methodologies a rep carries: BANT for fast first-call triage, and consultative selling for the discovery that turns “pain” from a checkbox into a number the buyer owns. All of it ladders up to one playbook, which is what the sales playbook guide is for.

The letters are common property. Any team can learn them over lunch, and most have. Your edge was never the acronym. It is whether your reps run the test on real deals when the number is due and the champion goes dark, and whether you can see that they did. We built Supered as the Behavior Layer for exactly that: it puts the right qualification question in front of the rep in the moment they are working the deal, and measures whether the answer is evidence or a hopeful morning. The vitals only keep the diagnosis honest if someone takes them.